阿斯利康中国架构大调整,高管变动引关注

生物科技馆
Yesterday

今日,阿斯利康中国掀起了一场备受瞩目的组织架构变革,此次调整堪称 2025 年规模最大的一次。在人事方面,不仅迎来新的人事任命,同时也有三位高管即将离任。一直以来,阿斯利康(业内常简称为 AZ)都备受行业内外关注。回顾过往二十余载,阿斯利康中国凭借旗下众多王牌产品以及团队卓越的执行力,在慢病治疗领域构建起强大的竞争优势。近年来,其在生物制药业务领域更是成果丰硕、进展显著。据内部消息透露,到 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10